Skip to main content

Drug Interactions between Cytotec and dinoprostone topical

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

miSOPROStol dinoprostone topical

Applies to: Cytotec (misoprostol) and dinoprostone topical

ADJUST DOSING INTERVAL: The use of oxytocic agents in combination with each other may result in additive pharmacodynamic effects, including stimulation of uterine hypertonus, which can lead to uterine rupture or cervical laceration, particularly in the presence of an undilated or poorly dilated cervix.

MANAGEMENT: Some authorities consider the concomitant use of dinoprostone with other oxytocic agents to be contraindicated. Concomitant use of dinoprost or carboprost with other oxytocic agents is generally not recommended. If necessary, administration of other oxytocic agent(s) should not be started until at least 6 to 12 hours after the insertion of dinoprostone vaginal gel, or at least 30 minutes after the removal of the dinoprostone vaginal insert. Recommended time intervals vary by brand and manufacturer. It is recommended to refer to local guidelines or drug product labeling.

References

  1. "Product Information. Prostin E2 (dinoprostone topical)." Apothecon Inc (2022):
  2. "Product Information. Prostin E2 (dinoprostone topical)." Pharmacia and Upjohn (2002):
  3. "Product Information. Prostin F2A (dinoprost)." Pharmacia Canada Inc (2002):
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  5. Cerner Multum, Inc. "Australian Product Information." O 0
  6. "Product Information. Carboprost (Reach) (carboprost)." Reach Pharmaceuticals Pty Ltd 08 (2023):
View all 6 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Prostaglandin abortifacients

Therapeutic duplication

The recommended maximum number of medicines in the 'prostaglandin abortifacients' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'prostaglandin abortifacients' category:

  • Cytotec (misoprostol)
  • dinoprostone topical

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer